An open-label study of the therapeutic efficacy of high-dose famotidine adjuvant pharmacotherapy in schizophrenia: Preliminary evidence for treatment efficacy

Clinical Neuropharmacology

Volumn 19, Issue 4, 1996, Pages 341-348

  Rosse, Richard B ^a   Kendrick, Kathie ^a   Fay McCarthy, Maureen ^a   Prell, George D ^b   Rosenberg, Paul ^a   Tsui, Lorraine C ^a   Wyatt, Richard Jed ^c   Deutsch, Stephen I ^a,d  

^a GEORGETOWN UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b MOUNT SINAI SCHOOL OF MEDICINE   (United States)

^c NATIONAL INSTITUTE OF MENTAL HEALTH   (United States)

^d DEPARTMENT OF VETERANS AFFAIRS   (United States)

Author keywords

Adjuvant therapy; Famotidine; Schizophrenia

Indexed keywords

FAMOTIDINE; HISTAMINE H2 RECEPTOR ANTAGONIST; NEUROLEPTIC AGENT;

ADJUVANT THERAPY; ADULT; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG MEGADOSE; HUMAN; NEGATIVE SYNDROME; PRIORITY JOURNAL; SCHIZOIDISM; SCHIZOPHRENIA;

EID: 0029927065     PISSN: 03625664     EISSN: None     Source Type: Journal    
DOI: 10.1097/00002826-199619040-00007     Document Type: Article

References (15)

1. Kaminsky R, Moriarty TM, Bodine S, Wolf DE, Davidson M. Effect of famotidine on deficit symptoms of schizophrenia. Lancet 1990;335:1351-2.
2. Deutsch SI, Rosse RB, Kendrick KA, Fay-McCarthy M, Collins JP, Wyatt RJ. Famotidine adjunctive pharmacotherapy for schizophrenia: preliminary data. Clin Neuropharmacol 1993;16:518-24.
3. Overall JE, Gorham DE. The Brief Psychiatric Rating Scale. Psychol Rep 1961;10:799-812.
4. Bonato GW. Manual for the ECDU assessment battery. 2nd rev. Washington, DC: U.S. Department of Health and Human Services, 1970.
5. Andreasen NC, Olsen S. Negative versus positive schizophrenia. Arch Gen Psychiatry 1982;39:784-8.
6. Mason AS, Granacher RP. Clinical handbook of antipsychotic drug therapy. New York: Brunner Mazel, 1980:33-4.
7. Gur RE, Mozley PD, Resnick SM, et al. Relations among clinical scales in schizophrenia. Am J Psychiatry 1991;148:472-8.
8. Oyewumi LK, Vollick D, Merskey H, Plumb C. Famotidine as an adjunctive treatment of resistant schizophrenia. J Psychiatr Neurosci 1994;19:145-50.
9. Kagevi I, Thorhallsson E, Wahlby L. CSF concentrations of famotidine. Br J Clin Pharmacol 1987;24:849-50.
10. Yoshimoto K, Saima S, Echizen H, et al. Famotidine-associated central nervous system reactions and plasma and cerebrospinal drug concentrations in neurosurgical patients with renal failure. Clin Pharmacol Ther 1994;55:693-700.
11. Martinez-Mir MI, Pollard H, Moreau J, et al. Loss of striatal histamine H2 receptors in Huntington's chorea but not in Parkinson's disease: comparison with animal models. Synapse 1993;15:209-20.
12. Elkashef AM, Buchanan RW, Gellad F, Munson RC, Breirer A. Basal ganglia pathology in schizophrenia and tardive dyskinesia: an MRI quantitative study. Am J Psychiatry 1994;151:752-5.
13. Early TS, Posner MI, Reiman EM, Raichle ME. Left striato-pallidal hyperactivity in schizophrenia. Part II: phenomenology and thought disorder. Psychiatr Dev 1989;2:109-21.
14. Early TS, Posner MI. Reiman EM, Raichle ME. Hyperactivity of the left striato-pallidal projection. Part I: lower level theory. Psychiatr Dev 1989;2:85-108.
15. Ellison G. Stimulant-induced psychosis, the dopamine theory of schizophrenia, and the habenula. Brain Res Rev 1994;19:223-39.